Acid-suppressive effects of generic omeprazole: Comparison of three brands of generic omeprazole with original omeprazole

Digestive and Liver Disease

Volumn 38, Issue 8, 2006, Pages 554-559

  Shimatani, T ^a   Inoue, M ^b   Kuroiwa, T ^b   Xu, J ^b   Mieno, H ^c   Tazuma, S ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA GENERAL HOSPITAL   (Japan)

Author keywords

Generic product; Intragastric pH; Omeprazole

Indexed keywords

CYTOCHROME P450 2C19; GENERIC DRUG; OMEPRAZOLE; OMEPRAZOLE TOWA; OMERAP; OVULANZE; PLACEBO;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEAL; NIGHT; NORMAL HUMAN; OPEN STUDY; PH MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; TIME; WILCOXON SIGNED RANKS TEST;

ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUGS, GENERIC; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GENOTYPE; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; JAPAN; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROSPECTIVE STUDIES; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 33748489515     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.01.032     Document Type: Article

References (37)

1. Hallerback B., Unge P., Carling L., Edwin B., Glise H., Havu N., et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 107 (1994) 1305-1311
2. 2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 91 (1996) 1758-1765
3. Gough A.L., Long R.G., Cooper B.T., Fosters C.S., Garrett A.D., and Langworthy C.H. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 10 (1996) 529-539
4. Harris R.A., Kuppermann M., and Richter J.E. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 92 (1997) 2179-2187
5. Andersson T., Miners J.O., Veronese M.E., Tassaneeyakul W., Tassaneeyakul W., Meyer U.A., et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36 (1993) 521-530
6. Chang M., Dahl M.L., Tybring G., Gotharson E., and Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5 (1995) 358-363
7. Chang M., Tybring G., Dahl M.L., Gotharson E., Sagar M., Seensalu R., et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39 (1995) 511-518
8. Kubota T., Chiba K., and Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60 (1996) 661-666
9. Ishizaki T., and Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl. 3 (1999) 27-36
10. Furuta T., Ohashi K., Kosuge K., Zhao X.J., Takashima M., Kimura M., et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65 (1999) 552-561
11. Adachi K., Katsube T., Kawamura A., Takashima T., Yuki M., Amano K., et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 14 (2000) 1259-1266
12. Shirai N., Furuta T., Moriyama Y., Okochi H., Kobayashi K., Takashima M., et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15 (2001) 1929-1937
13. Shirai N., Furuta T., Xiao F., Kajimura M., Hanai H., Ohashi K., et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 16 (2002) 837-846
14. 2-receptor antagonist. Aliment Pharmacol Ther 18 (2003) 1149-1157
15. Shimatani T., Inoue M., Kuroiwa T., and Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 19 (2004) 113-122
16. Peny J.M. How bright is the future for generics?. Scrip Mag (2003) 13-17
17. Mikami H., Ikemoto M., Yoshiyama I., and Tatsuki H. Bioequivalence evaluation of omeprazole 10 mg and 20 mg tablet in healthy volunteer. J Med Pharm Sci 51 (2004) 891-901 (in Japanese)
18. http://www.taiyo-yakuhin.com/dinet/file/data/1/1/01/1101_OVULANZE_tab_P.I.pdf (in Japanese)
19. http://www.nichiiko.co.jp/medicine/be/be_pdf/o_p/omerap10_be.pdf (in Japanese)
20. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
21. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
22. Peghini P.L., Katz P.O., Bracy N.A., and Castell D.O. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93 (1998) 763-767
23. Varanasi R.V., Fantry G.T., and Wilson K.T. Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Helicobacter 3 (1998) 188-194
24. Koike T., Ohara S., Sekine H., Iijima K., Abe Y., Kato K., et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 94 (1999) 3468-3472
25. El-Omar E.M., Penman I.D., Ardill J.E., Chittajallu R.S., Howie C., and McColl K.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109 (1995) 681-691
26. El-Omar E.M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
27. Ohara S., Kimpara T., Sekine H., Moriyama S., Kato K., Nakayama Y., et al. Comparison of acid-inhibitory effect of omeprazole in before-breakfast dosing and after-breakfast dosing. Jpn Pharmacol Ther 23 (1995) 879-885 (in Japanese)
28. Nakashima M., Kanamaru M., Hashimoto H., Takiguchi Y., Mizuno A., Kajiho H., et al. Phase I study of omeprazole-single-dose and multiple-dose studies. Jpn J Clin Pharmacol Ther 19 (1988) 667-679 (in Japanese)
29. Andersson T., Andren K., Cederberg C., Heggelund A., Lundborg P., and Rohss K. Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seven days of treatment. Drug Invest 2 (1990) 184-188
30. http://www.nihs.go.jp/drug/be-guide(e)/Generic/be97E.html
31. Garg S.K., Chugh Y., Tripathi S.K., Kumar N., and Sharma P.L. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 31 (1993) 96-99
32. Pillai G.K., Salem M.S., Najib N.M., Jilani J., Hasan M.M., Ghanem E., et al. Bioequivalence study of two capsule formulations of omeprazole. Acta Pharm Hung 66 (1996) 231-235
33. Thomson A.B., Kirdeikis P., Lastiwka R., Rohss K., Sinclair P., and Olofsson B. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients. Can J Gastroenterol 11 (1997) 657-660
34. Farinha A., Bica A., Pais J.P., Toscano M.C., and Tavares P. Bioequivalence evaluation of two omeprazole enteric-coated formulations in humans. Eur J Pharm Sci 7 (1999) 311-315
35. Elkoshi Z., Behr D., Mirimsky A., Tsvetkov I., and Danon A. Multiple-dose studies can more sensitive assessment for bioequivalence than single-dose studies. Clin Drug Invest 22 (2002) 1-9
36. Kadowaki Y., Nakayama D., Sakuma S., and Yamashita S. Pharmacological assessment of originally approved medicine and generic-dissolution test of omeprazole 20 mg tablets. J Med Pharm Sci 54 (2005) 189-193 (in Japanese)
37. Niv Y. Comparison of proton pump inhibitor-based triple therapy with Losec and the generic drug, Omepradex, for efficacy of Helicobacter pylori eradication. Dig Dis Sci 50 (2005) 623-625